Flow cytometric patterns in blood from dogs with non‐neoplastic and neoplastic hematologic diseases using double labeling for CD18 and CD45

Abstract

Double labeling for CD18/CD45 may be useful as a screening method to evaluate hematologic diseases and help determine cell lineage, and to aid in the selection of a panel of antibodies that would be useful for further analysis.

Flow Cytometry in Veterinary Oncology

“…Flow cytometric comparison of benign and malignant canine lymphocytes identified relative downregulation of CD18 and CD45 on neoplastic cells, potentially limiting their use as universal leukocyte markers. 15,30 These findings corroborate that CD18 detection in formalin-fixed round cell tumors suggests histiocytic or granulocytic origin rather than lymphocytic origin.…”

Flow‐cytometric detection of phenotypic aberrancies in canine small clear cell lymphoma

“…In particular, CD45 expression was lost in all small clear cell lymphoma cases but one. CD45 is a pan‐leukocyte marker in the dog, with different degree of expression in the leukocytes subclasses . None of the reactive samples included in this study as negative controls had a CD45‐negative lymphoid population.…”

Identification of neoplastic cells in blood using the Sysmex XT‐2000iV: a preliminary step in the diagnosis of canine leukemia

“…Flow cytometric analysis was performed on cells from peripheral blood and bone marrow in all the cases ( n =96) in which leukemia was suspected on the basis of finding severely increased WBC counts, the presence of immature or atypical circulating cells, or a neoplasm on cytologic evaluation of lymph nodes and/or spleen. The panel of antibodies and the flow cytometric method used were described in a previous study 3 . In 2 cases of megakaryoblastic leukemia, the cells were typed by immunocytochemical analysis using a murine anti‐CD61 monoclonal antibody (anti‐human gpIIIa, Clone Y2/51, Dako, Glostrup, Denmark) and a rabbit anti‐vWF polyclonal antibody (anti‐factor VIII related antigen, Dako), as described previously 15…”

“…Correct diagnosis and classification of myeloid and lymphoid leukemias may not be possible by routine examination of peripheral blood smears 1 and may require advanced techniques such as flow cytometry or molecular methods 2,3 . An automated screen for neoplastic changes in peripheral blood could more effectively and rapidly identify patients needing definitive diagnostic testing and might also guide chemotherapy.…”